PLEASANTON, Calif., May 7, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its first quarter, which ended April 30, 2025, after market close on May 28, 2025. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.
Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.
Event: | Veeva Systems' Fiscal 2026 First Quarter Results Conference Call |
Date: | Wednesday, May 28, 2025 |
Time: | 2:00 p.m. PT (5:00 p.m. ET) |
Conference Call Registration: https://registrations.events/direct/Q4I261717 | |
Webcast: | |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact:
Gunnar Hansen
Veeva Systems Inc.
267-460-5839
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Maria Scurry
Veeva Systems Inc.
781-366-7617
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$239.95 |
| Daily Change: | 4.21 1.79 |
| Daily Volume: | 1,660,307 |
| Market Cap: | US$39.330B |
November 24, 2025 November 20, 2025 November 04, 2025 October 16, 2025 October 14, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load